Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

626 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models.
Wong CW, Evangelou C, Sefton KN, Leshem R, Zhang W, Gopalan V, Chattrakarn S, Fernandez Carro ML, Uzuner E, Mole H, Wilcock DJ, Smith MP, Sergiou K, Telfer BA, Isaac DT, Liu C, Perl NR, Marie K, Lorigan P, Williams KJ, Rao PE, Nagaraju RT, Niepel M, Hurlstone AFL. Wong CW, et al. Among authors: williams kj. Nat Commun. 2023 Sep 26;14(1):5983. doi: 10.1038/s41467-023-41737-1. Nat Commun. 2023. PMID: 37752135 Free PMC article.
Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism Accompany Melanocyte Neoplasia Progression in Zebrafish.
Henderson F, Johnston HR, Badrock AP, Jones EA, Forster D, Nagaraju RT, Evangelou C, Kamarashev J, Green M, Fairclough M, Ramirez IB, He S, Snaar-Jagalska BE, Hollywood K, Dunn WB, Spaink HP, Smith MP, Lorigan P, Claude E, Williams KJ, McMahon AW, Hurlstone A. Henderson F, et al. Among authors: williams kj. Cancer Res. 2019 May 1;79(9):2136-2151. doi: 10.1158/0008-5472.CAN-18-2409. Epub 2019 Mar 12. Cancer Res. 2019. PMID: 30862716
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ. Ali M, et al. Among authors: williams kj. Mol Cancer Ther. 2011 Dec;10(12):2320-9. doi: 10.1158/1535-7163.MCT-11-0356. Epub 2011 Sep 16. Mol Cancer Ther. 2011. PMID: 21926192 Free PMC article.
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.
McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T. McCrudden CM, et al. Among authors: williams kj. PLoS One. 2015 Feb 17;10(2):e0118187. doi: 10.1371/journal.pone.0118187. eCollection 2015. PLoS One. 2015. PMID: 25689628 Free PMC article.
626 results